Vaxart Secures Additional BARDA Funding, Announces Imminent COVID-19 Trial Data Amidst Proxy Contest
Summary
Vaxart filed additional proxy materials, announcing a new $29 million BARDA funding release and an imminent data readout for its Phase 2b COVID-19 trial, while actively campaigning for its current board in an ongoing proxy contest.
Key Events
-
Increased BARDA Funding
Vaxart announced a modification to its BARDA contract, releasing an additional $29 million for its Phase 2b COVID-19 trial, bringing total funding to approximately $345 million.
-
Imminent Phase 2b Data Readout
The company expects to report 12-month safety and immunogenicity data from the 400-participant Sentinel Cohort of its BARDA-funded Phase 2b COVID-19 trial "in the coming weeks."
-
Active Proxy Contest
Vaxart is actively soliciting shareholder votes to re-elect its current board of directors, defending against a dissident shareholder group that holds 0.5% of outstanding shares.
-
Board's Defense Strategy
The filing highlights the current board's achievements, including extending the cash runway into Q2 2027 and securing a Dynavax partnership, while criticizing the dissident nominees' lack of relevant experience and credible alternative plans.
Analysis
This filing serves as additional definitive proxy material, where Vaxart's board defends its performance and urges shareholders to vote for its nominees. Crucially, it reveals a new BARDA contract modification, releasing an additional $29 million for the Phase 2b COVID-19 trial and confirming that 12-month data from the Sentinel Cohort will be reported "in the coming weeks." This update provides significant financial support and a near-term catalyst for the company's lead program, which is a key argument for the current board's effectiveness in the ongoing proxy contest.
At the time of this filing, VXRT was trading at $0.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $122.7M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.